This content is machine translated Venous thromboembolism prevention PCSK9 inhibitors: Current evidence, mechanisms and unanswered questions Venous thromboembolism (VTE), consisting of deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cause of cardiovascular mortality worldwide after myocardial infarction and stroke. Despite continuous...…
View Post 7 min This content is machine translated ACC 2018 Success story of PCSK9 inhibition continues For the first time after the highly acclaimed FOURIER trial, a PCSK9 inhibitor now also shows a mortality benefit in secondary prevention. The product in question is alirocumab. Experts are…
